{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:26:44Z","timestamp":1760909204316,"version":"3.37.3"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T00:00:00Z","timestamp":1557446400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00520-019-04816-y","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T11:20:57Z","timestamp":1557487257000},"page":"3209-3217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of anticoagulation in patients with metastatic castration\u2013resistant prostate cancer receiving abiraterone + prednisone"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3847-4899","authenticated-orcid":false,"given":"Samuel","family":"Dubinsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alia","family":"Thawer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne G.","family":"McLeod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.J.","family":"McFarlane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urban","family":"Emmenegger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,10]]},"reference":[{"issue":"6","key":"4816_CR1","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00345-017-2038-0","volume":"35","author":"MR Cooperberg","year":"2017","unstructured":"Cooperberg MR, Chan JM (2017) Epidemiology of prostate cancer. World J Urol 35(6):849. https:\/\/doi.org\/10.1007\/s00345-017-2038-0","journal-title":"World J Urol"},{"key":"4816_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegal RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87\u2013108. https:\/\/doi.org\/10.3322\/caac.21262","journal-title":"CA Cancer J Clin"},{"issue":"20","key":"4816_CR3","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1001\/archinte.164.20.2260","volume":"164","author":"PD Stein","year":"2004","unstructured":"Stein PD, Hull RD, Kayali F et al (2004) Venous thromboembolism according to age: the impact of an aging population. Arch Intern Med 164(20):2260\u20132265","journal-title":"Arch Intern Med"},{"key":"4816_CR4","doi-asserted-by":"publisher","unstructured":"Marinigh R, Lip GYH, Fiotti N, Giansanate C, Lane DA (2010) Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. JACC 56(11). https:\/\/doi.org\/10.1016\/j.jacc.2010.05.028","DOI":"10.1016\/j.jacc.2010.05.028"},{"key":"4816_CR5","doi-asserted-by":"publisher","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","volume":"27","author":"AA Khorana","year":"2009","unstructured":"Khorana AA, Connolly GC (2009) Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 27:4839\u20134847. https:\/\/doi.org\/10.1200\/JCO.2009.22.3271","journal-title":"J Clin Oncol"},{"key":"4816_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/pcan.2016.30","volume":"19","author":"AB Weiner","year":"2016","unstructured":"Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM (2016) Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis 19:395\u2013397. https:\/\/doi.org\/10.1038\/pcan.2016.30","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4816_CR7","doi-asserted-by":"publisher","unstructured":"Lane DA, Skjoth F, Lip GYH, Larsen TB, Kotecha D (2017) Temporal trends in incidence, prevalence, and mortality of atrial fibrillation in primary care. JAHA 6(5). https:\/\/doi.org\/10.1161\/JAHA.116.00515","DOI":"10.1161\/JAHA.116.00515"},{"issue":"2","key":"4816_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3747\/co.22.2586","volume":"22","author":"JC Easaw","year":"2015","unstructured":"Easaw JC, Shea-Budgell MA, Wu CMJ et al (2015) Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis. Curr Oncol 22(2):133\u2013143. https:\/\/doi.org\/10.3747\/co.22.2586","journal-title":"Curr Oncol"},{"key":"4816_CR9","doi-asserted-by":"publisher","first-page":"e1001275","DOI":"10.1371\/journal.pmed.1001275","volume":"9","author":"F Horsted","year":"2012","unstructured":"Horsted F, West J, Grainge MJ (2012) Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 9:e1001275. https:\/\/doi.org\/10.1371\/journal.pmed.1001275","journal-title":"PLoS Med"},{"key":"4816_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/DDDT.S15850","volume":"6","author":"Y Rehman","year":"2012","unstructured":"Rehman Y, Rosenberg JE (2012) Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des Devel Ther 6:13\u201318. https:\/\/doi.org\/10.2147\/DDDT.S15850","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"4816_CR11","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2217\/fon.10.48","volume":"6","author":"N Agarwal","year":"2010","unstructured":"Agarwal N, Hutson TE, Sonpavde G, Vogelzang (2010) Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. Future Oncol 6(5):665\u2013679. https:\/\/doi.org\/10.2217\/fon.10.48","journal-title":"Future Oncol"},{"issue":"1\u20132","key":"4816_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jsbmb.2010.11.005","volume":"125","author":"RD Bruno","year":"2011","unstructured":"Bruno RD, Njar VCO, Vasaitis TS (2011) CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol 125(1\u20132):23\u201331. https:\/\/doi.org\/10.1016\/j.jsbmb.2010.11.005","journal-title":"J Steroid Biochem Mol Biol"},{"key":"4816_CR13","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono J et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138\u2013148. https:\/\/doi.org\/10.1056\/NEJMoa1209096","journal-title":"N Engl J Med"},{"key":"4816_CR14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR et al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377:388\u2013351. https:\/\/doi.org\/10.1056\/NEJMoa1702900","journal-title":"N Engl J Med"},{"key":"4816_CR15","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran NP, Fein L et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352\u2013360. https:\/\/doi.org\/10.1056\/NEJMoa1704174","journal-title":"N Engl J Med"},{"issue":"6","key":"4816_CR16","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1517\/17425255.2015.1041918","volume":"11","author":"CS Han","year":"2015","unstructured":"Han CS, Kim IY, Patel R (2015) Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer. Expert Opin Drug Metab Toxicol 11(6):967\u2013975. https:\/\/doi.org\/10.1517\/17425255.2015.1041918","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"4816_CR17","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s40262-016-0403-6","volume":"55","author":"GE Benoist","year":"2016","unstructured":"Benoist GE, Hendriks RJ, Mulders PFA et al (2016) Pharmacokinetic aspect of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide. Clin Pharmacokinet 55(11):1369\u20131380. https:\/\/doi.org\/10.1007\/s40262-016-0403-6","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"4816_CR18","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.ctrv.2013.03.003","volume":"39","author":"A Pia","year":"2013","unstructured":"Pia A, Vignani F, Attard G et al (2013) Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. Cancer Treat Rev 39(8):966\u2013973. https:\/\/doi.org\/10.1016\/j.ctrv.2013.03.003 . Review","journal-title":"Cancer Treat Rev"},{"key":"4816_CR19","doi-asserted-by":"publisher","unstructured":"Narum S, Westergren T, Klemp M (2014) Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open 4(5). https:\/\/doi.org\/10.1136\/bmjopen-2013-004587","DOI":"10.1136\/bmjopen-2013-004587"},{"key":"4816_CR20","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/ajg.2009.115","volume":"104","author":"FL Lanza","year":"2009","unstructured":"Lanza FL, Chan FKL, Quigley EMM et al (2009) Prevention of NSAID-related ulcer complications. Am J Gastroenterol 104:728\u2013738. https:\/\/doi.org\/10.1038\/ajg.2009.115","journal-title":"Am J Gastroenterol"},{"key":"4816_CR21","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:632\u2013634","journal-title":"J Thromb Haemost"},{"issue":"10","key":"4816_CR22","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.cjca.2016.07.591","volume":"32","author":"L Macle","year":"2016","unstructured":"Macle L, Cairns J, Leblanc L et al (2016) 2016 focused update of the Canadian cardiovascular society guidelines for the management of atrial fibrillation. CJC 32(10):1170\u20131185. https:\/\/doi.org\/10.1016\/j.cjca.2016.07.591","journal-title":"CJC"},{"issue":"12","key":"4816_CR23","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/j.amjcard.2017.08.038","volume":"120","author":"R Patel","year":"2017","unstructured":"Patel R, Gutierrez A, Rybicki L, Khorana AA (2017) Usefulness of CHADS2 and CHA2DS2-VASc scores for stroke prediction in patients with cancer and atrial fibrillation. Am J Cardiol 120(12):2182\u20132186","journal-title":"Am J Cardiol"},{"issue":"7","key":"4816_CR24","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1182\/blood-2014-03-563056","volume":"124","author":"CH Yeh","year":"2014","unstructured":"Yeh CH, Gross PL, Weitz JI (2014) Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood. 124(7):1020\u20131028","journal-title":"Blood."},{"key":"4816_CR25","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3324\/haematol.2012.073338","volume":"98","author":"B Dickmann","year":"2013","unstructured":"Dickmann B, Ahlbrecht J, Ay C, Dunkler D, Thaler J, Scheithauer W, Quehenberger P, Zielinski C, Pabinger I (2013) Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica. 98:1309\u20131314. https:\/\/doi.org\/10.3324\/haematol.2012.073338","journal-title":"Haematologica."},{"issue":"5","key":"4816_CR26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(10)70038-3","volume":"11","author":"MV Van Hemelrijck","year":"2010","unstructured":"Van Hemelrijck MV, Adolfsson J, Garmo H et al (2010) Risk of thromboembolic disease in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol 11(5):450\u2013458. https:\/\/doi.org\/10.1016\/S1470-2045(10)70038-3","journal-title":"Lancet Oncol"},{"issue":"11","key":"4816_CR27","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s00228-016-2120-3","volume":"72","author":"R Jamani","year":"2016","unstructured":"Jamani R, Lee EK, Berry SR et al (2016) High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate. Eur J Clin Pharmacol 72(11):1391\u20131399","journal-title":"Eur J Clin Pharmacol"},{"key":"4816_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4137\/CMO.S18991","volume":"8","author":"G Elyamany","year":"2014","unstructured":"Elyamany G, Alzahrani AM, Bukary E (2014) Cancer-associated thrombosis: an overview. Clin Med Insights Oncol 8:129\u2013137","journal-title":"Clin Med Insights Oncol"},{"issue":"2","key":"4816_CR29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1378\/chest.11-2301","volume":"141","author":"C Kearon","year":"2012","unstructured":"Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE. CHEST. 141(2):419\u2013494","journal-title":"CHEST."},{"issue":"11","key":"4816_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.amjmed.2016.06.003","volume":"129","author":"J Eikelboom","year":"2016","unstructured":"Eikelboom J, Merli G (2016) Bleeding with direct oral anticoagulants vs. warfarin: clinical experience. Am J Med 129(11):33\u201340. https:\/\/doi.org\/10.1016\/j.amjmed.2016.06.003","journal-title":"Am J Med"},{"issue":"9","key":"4816_CR31","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s40264-016-0443-8","volume":"39","author":"JL Fitzgerald","year":"2016","unstructured":"Fitzgerald JL, Howes LG (2016) Drug interactions of direct acting oral anticoagulants. Drug Saf 39(9):841\u2013845. https:\/\/doi.org\/10.1007\/s40264-016-0443-8","journal-title":"Drug Saf"},{"key":"4816_CR32","doi-asserted-by":"crossref","unstructured":"Di Minno A, Frigerio B, Spadarella G. et. al. Old and new oral anticoagulants: food, herbal medicines and drug interactions. Blood Rev 2017; 31(4): 193\u2013203","DOI":"10.1016\/j.blre.2017.02.001"},{"key":"4816_CR33","doi-asserted-by":"publisher","first-page":"j2216","DOI":"10.1136\/bmj.j2216","volume":"357","author":"A Burnett","year":"2017","unstructured":"Burnett A, Siegal D, Crowther M (2017) Specific antidotes for bleeding associated with direct oral anticoagulants. BMJ 357:j2216. https:\/\/doi.org\/10.1136\/bmj.j2216","journal-title":"BMJ"},{"key":"4816_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11239-015-1314-3","volume":"41","author":"EA Nutescu","year":"2016","unstructured":"Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A (2016) Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis 41:15\u201331. https:\/\/doi.org\/10.1007\/s11239-015-1314-3","journal-title":"J Thromb Thrombolysis"},{"key":"4816_CR35","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Jyotsna G (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883\u2013891. https:\/\/doi.org\/10.1056\/NEJMoa1009638","journal-title":"N Engl J Med"},{"key":"4816_CR36","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"EINSTEIN Investigators","year":"2010","unstructured":"EINSTEIN Investigators (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499\u20132510. https:\/\/doi.org\/10.1056\/NEJMoa1007903","journal-title":"N Engl J Med"},{"key":"4816_CR37","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"EINSTEIN-PE Investigators","year":"2012","unstructured":"EINSTEIN-PE Investigators (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287\u20131297. https:\/\/doi.org\/10.1056\/NEJMoa1113572","journal-title":"N Engl J Med"},{"key":"4816_CR38","doi-asserted-by":"publisher","unstructured":"Young A, Marshall A, Thirlwall J et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol:JCO2018788034. https:\/\/doi.org\/10.1200\/JCO.2018.78.8034","DOI":"10.1200\/JCO.2018.78.8034"},{"key":"4816_CR39","volume-title":"Xarelto product monograph","author":"Bayer INC","year":"2018","unstructured":"Bayer INC (2018) Xarelto product monograph. Bayer INC., Mississauga"},{"key":"4816_CR40","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"269","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 269:2093\u20132104. https:\/\/doi.org\/10.1056\/NEJMoa1310907","journal-title":"N Engl J Med"},{"key":"4816_CR41","volume-title":"Lixiana product monograph","author":"Servier Pharmaceuticals","year":"2016","unstructured":"Servier Pharmaceuticals (2016) Lixiana product monograph. Servier Canada INC., Laval"},{"key":"4816_CR42","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"Hokusai-VTE Investigators","year":"2013","unstructured":"Hokusai-VTE Investigators (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406\u20131415. https:\/\/doi.org\/10.1056\/NEJMoa1306638","journal-title":"N Engl J Med"},{"key":"4816_CR43","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378:615\u2013624. https:\/\/doi.org\/10.1056\/NEJMoa1711948","journal-title":"N Engl J Med"},{"key":"4816_CR44","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","volume":"55","author":"DA Parasrampuria","year":"2016","unstructured":"Parasrampuria DA, Truitt KE (2016) Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet 55:641\u2013655. https:\/\/doi.org\/10.1007\/s40262-015-0342-7","journal-title":"Clin Pharmacokinet"},{"key":"4816_CR45","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992. https:\/\/doi.org\/10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"key":"4816_CR46","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799\u2013808. https:\/\/doi.org\/10.1056\/NEJMoa1302507","journal-title":"N Engl J Med"},{"key":"4816_CR47","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1111\/jth.13153","volume":"13","author":"G Agnelli","year":"2015","unstructured":"Agnelli G, Buller HR, Cohen A et al (2015) Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 13:2187\u20132191","journal-title":"J Thromb Haemost"},{"issue":"6","key":"4816_CR48","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","volume":"33","author":"GH Lyman","year":"2015","unstructured":"Lyman GH, Bohlke K, Khorana AA et al (2015) Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update 2014. J Clin Oncol 33(6):654\u2013656","journal-title":"J Clin Oncol"},{"key":"4816_CR49","doi-asserted-by":"publisher","first-page":"838","DOI":"10.6004\/jnccn.2006.0071","volume":"4","author":"LD Wagman","year":"2006","unstructured":"Wagman LD, Baird MF, Bennett CL et al (2006) Venous thromboembolic disease: clinical practice guidelines in oncology. J Natl Compr Cancer Netw 4:838\u2013869","journal-title":"J Natl Compr Cancer Netw"},{"key":"4816_CR50","volume-title":"Eliquis product monograph","author":"Pfizer Pharmaceuticals","year":"2016","unstructured":"Pfizer Pharmaceuticals (2016) Eliquis product monograph. Pfizer Canada INC., Kirkland"},{"key":"4816_CR51","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139\u20131151. https:\/\/doi.org\/10.1056\/NEJMoa0905561","journal-title":"N Engl J Med"},{"key":"4816_CR52","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342\u20132352. https:\/\/doi.org\/10.1056\/NEJMoa0906598","journal-title":"N Engl J Med"},{"issue":"1","key":"4816_CR53","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1053\/j.gastro.2013.02.041","volume":"145","author":"IL Holster","year":"2013","unstructured":"Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ETTL (2013) New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 145(1):105\u2013112. https:\/\/doi.org\/10.1053\/j.gastro.2013.02.041","journal-title":"Gastroenterology"},{"key":"4816_CR54","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1136\/bmj.h1857","volume":"350","author":"NS Abraham","year":"2015","unstructured":"Abraham NS, Singh S, Alexander GC et al (2015) Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 350:1857. https:\/\/doi.org\/10.1136\/bmj.h1857","journal-title":"BMJ"},{"key":"4816_CR55","volume-title":"Pradaxa product monograph","author":"Boehringer Ingelhem Pharmaceuticals","year":"2016","unstructured":"Boehringer Ingelhem Pharmaceuticals (2016) Pradaxa product monograph. Boehringer Ingelheim Canada Ltd, Burlington"},{"key":"4816_CR56","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AYY Lee","year":"2003","unstructured":"Lee AYY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146\u2013153. https:\/\/doi.org\/10.1056\/NEJMoa025313","journal-title":"N Engl J Med"},{"issue":"2","key":"4816_CR57","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1378\/chest.14-0402","volume":"147","author":"MC Vedovati","year":"2015","unstructured":"Vedovati MC, Germini F, Agnelli G, Becattini C (2015) Direct oral anticoagulants in patients with VTE and cancer. CHEST. 147(2):475\u2013483","journal-title":"CHEST."},{"issue":"9S","key":"4816_CR58","doi-asserted-by":"publisher","first-page":"182S","DOI":"10.1177\/1076029618800792","volume":"24","author":"DM Sobieraj","year":"2018","unstructured":"Sobieraj DM, Baker WL, Smith E et al (2018) Anticoagulation for the treatment of cancer-associated thrombosis: a systematic review and network meta-analysis of randomized trials. Clin Appl Thromb Hemost 24(9S):182S\u2013187S. https:\/\/doi.org\/10.1177\/1076029618800792","journal-title":"Clin Appl Thromb Hemost"},{"issue":"3","key":"4816_CR59","first-page":"115","volume":"24","author":"AJ Camm","year":"2001","unstructured":"Camm AJ (2001) Atrial fibrillation: is there a role for low-molecular-weight heparin? Clin Cariol 24(3):115\u2013119","journal-title":"Clin Cariol"},{"key":"4816_CR60","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1345\/aph.1A208","volume":"36","author":"CD Sands","year":"2002","unstructured":"Sands CD, Chan ES, Welty TE (2002) Revisiting the significance of warfarin protein-binding displacement interactions. Ann Pharmacother 36:1642\u20131644","journal-title":"Ann Pharmacother"},{"issue":"3","key":"4816_CR61","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/jps.21916","volume":"99","author":"S Schmidt","year":"2010","unstructured":"Schmidt S, Gonzalez D, Derendorf H (2010) Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci 99(3):1107\u20131112. https:\/\/doi.org\/10.1002\/jps.21916","journal-title":"J Pharm Sci"},{"issue":"4","key":"4816_CR62","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1503\/cmaj.070946","volume":"177","author":"DN Juurlink","year":"2007","unstructured":"Juurlink DN (2007) Drug interactions with warfarin: what clinicians need to know. CMAJ. 177(4):369\u2013371","journal-title":"CMAJ."},{"issue":"2","key":"4816_CR63","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1378\/chest.11-2295","volume":"141","author":"A Holbrook","year":"2012","unstructured":"Holbrook A, Schulman S, Guyatt GH et al (2012) Evidence-based management of anticoagulant therapy. CHEST. 141(2):152\u2013184","journal-title":"CHEST."},{"issue":"2","key":"4816_CR64","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jacc.2017.03.011","volume":"70","author":"RA Nishimura","year":"2017","unstructured":"Nishimura RA, Otto CM, Bonow RO et al (2017) 2017 AHA\/ACC focused update of the 2014 AHA\/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. JACC. 70(2):252\u2013289","journal-title":"JACC."},{"key":"4816_CR65","doi-asserted-by":"publisher","unstructured":"Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest physicians evidence-based clinical practice guidelines. CHEST 141(2):576\u2013600. https:\/\/doi.org\/10.1378\/chest.11-2305","DOI":"10.1378\/chest.11-2305"},{"issue":"6","key":"4816_CR66","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.ahj.2012.03.011","volume":"163","author":"F Van de Werf","year":"2012","unstructured":"Van de Werf F, Brueckmann M, Connolly SJ et al (2012) A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). AHJ. 163(6):931\u2013937","journal-title":"AHJ."},{"issue":"1","key":"4816_CR67","first-page":"23","volume":"38","author":"T Goldberg","year":"2013","unstructured":"Goldberg T, Berrios-Colon E (2013) Abiraterone (Zytiga), a novel agent for the management of castration-resistant prostate cancer. PT. 38(1):23\u201326","journal-title":"PT."},{"key":"4816_CR68","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3747\/co.25.4266","volume":"5","author":"M Carrier","year":"2018","unstructured":"Carrier M, Blais N, Crowther M et al (2018) Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus. Curr Oncol 5:329\u2013337","journal-title":"Curr Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04816-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-019-04816-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04816-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T20:48:51Z","timestamp":1663447731000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-019-04816-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,10]]},"references-count":68,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["4816"],"URL":"https:\/\/doi.org\/10.1007\/s00520-019-04816-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2019,5,10]]},"assertion":[{"value":"10 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest. Dr. Urban Emmenegger has received clinical research support (personal and institutional) from Janssen Inc., Canada, and has attended advisory board meetings.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors of this manuscript have full control of the data presented. We agree to let the Journal of Supportive Care in Cancer review the data if requested.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}